

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8361119

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	INTRON BIOTECHNOLOGY, CO. LTD	12/20/2023
RECEIVING PARTY DATA		
Name:	MOLGENBIO CO., LTD	
Street Address:	141-101, 1 GWANAK-RO GWANAK-GU	
City:	SEOUL	
State/Country:	KOREA, REPUBLIC OF	
Postal Code:	08826	
PROPERTY NUMBERS Total: 3		
Property Type	Number	
Patent Number:	10226446	
Patent Number:	10576060	
Patent Number:	9505779	
CORRESPONDENCE DATA		
Fax Number:	(206)682-6031	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2066224900	
Email:	barbarah@seedip.com	
Correspondent Name:	QING LIN, PH.D.	
Address Line 1:	SEED IP LAW GROUP LLP	
Address Line 2:	701 FIFTH AVE, SUITE 5400	
Address Line 4:	SEATTLE, WASHINGTON 98104	
ATTORNEY DOCKET NUMBER:	481374.401USPC	
NAME OF SUBMITTER:	QING LIN, PH.D.	
SIGNATURE:	/Qing Lin/	
DATE SIGNED:	01/03/2024	
Total Attachments: 5		
source=US_Assignment_Molgenbio and Intron biotechnology-signed#page1.tif		
source=US_Assignment_Molgenbio and Intron biotechnology-signed#page2.tif		
source=US_Assignment_Molgenbio and Intron biotechnology-signed#page3.tif		

source=US_Assignment_Molgenbio and Intron biotechnology-signed#page4.tif

source=US_Assignment_Molgenbio and Intron biotechnology-signed#page5.tif

PATENT

REEL: 066189 FRAME: 0339

ASSIGNMENT

INTRON BIOTECHNOLOGY, CO., LTD (referred to as "ASSIGNOR"), having an address of 704, 703, 702, 701 137, Sagimskgol-ro Jungwon-gu Seongnam-si, Gyeonggido 13202, Republic of Korea, is an owner of one or more inventions described in the following application(s):

Jurisdiction and Application No.	Filing Date (MM/DD/YYYY)	Patent No.	Issue Date (MM/DD/YYYY)	Title
US 15/500,353	01/30/2017	10,226,446	03/12/2019	FK506 DERIVATIVE MAINTAINING NERVE REGENERATION ACTIVITY WITHOUT IMMUNOSUPPRESSIVE ACTIVITY, AND USE THEREOF
16/242,386	01/08/2019	10,576,060	03/03/2020	FK506 DERIVATIVE MAINTAINING NERVE REGENERATION ACTIVITY WITHOUT IMMUNOSUPPRESSIVE ACTIVITY, AND USE THEREOF
13/774,899	02/22/2013	9,505,779	11/29/2016	TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME

(referred to as the "Application(s)").

MOLGENBIO CO., LTD (referred to as "ASSIGNEE"), having an address of 141-101, 1 Gwanak-ro Gwanak-gu Seoul 08826 Republic of Korea is desirous of acquiring ASSIGNOR's entire right, title, and interest in and to the one or more inventions, the Application(s), and any letters patent which may be granted for the Application(s) and for any application claiming priority to any of the Application(s) in the United States and in any and all foreign jurisdictions.

In exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby sells, assigns, and transfers, or confirms the previous sale, assignment, and transfer, by law, agreement, or otherwise, to ASSIGNEE, ASSIGNOR's entire right, title, and interest in and to the one or more inventions, the Application(s), and any letters patent that may be granted for the Application(s), and for any application claiming priority to any of the Application(s) in the United States and all foreign jurisdictions, including any extensions or adjustments in term thereof, including divisions, continuations, continuations-in-part, and reissues thereof, including the right to file applications directly in the name of ASSIGNEE and to claim priority to any of the Application(s) and any application claiming priority to any of the Application(s) in the United States and in all foreign jurisdictions under any applicable legislation, convention, treaty, or otherwise, and further including the right to sue and obtain legal and equitable relief, including damages, profits, and injunctions, for past, present, and future infringement of any letters patent that may be granted for the Application(s) and for any application claiming priority to any of the Application(s); the Application(s), any application claiming priority to any of the Application(s), and any letters patent that may be granted for the Application(s) or for any application claiming priority to any of the Application(s) to be held and enjoyed by ASSIGNEE and their successors and assigns for their use and benefit as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had the sale, assignment, and transfer not been executed.

ASSIGNOR hereby authorizes the relevant authority to issue all letters patent on the Application(s) and any application claiming priority to any of the Application(s) to ASSIGNEE.

ASSIGNOR agrees to execute all instruments required for the filing and prosecution of the Application(s) and any application claiming priority to any of the Application(s), for litigation regarding any letters patent, or for the purpose of protecting title to the Application(s), or any application claiming priority to any of the Application(s), and any and all letters patent granted therefor. In the event the present Assignment is determined to be ineffective with respect to any portion of ASSIGNOR's right, title, and interest in and to the Application(s) or any

application claiming priority to any of the Application(s), ASSIGNOR agrees to assign ASSIGNOR's entire right, title, and interest in and to the Application(s) and any application claiming priority to any of the Application(s) to ASSIGNEE.

ASSIGNOR hereby authorizes Seed Intellectual Property Law Group LLP to insert the jurisdiction(s), application number(s), filing date(s), patent number(s), issue date(s), and title(s) of the Application(s) and any application claiming priority to any of the Application(s) above.

INTRON BIOTECHNOLOGY, CO., LTD


Date: Dec 20, 2023

 (ASSIGNOR)
Signature

Kang Sang Hyeon, Vice President
Printed Name, Title

MOLGENBIO CO., LTD

Date: Dec. 20. 2023

 (ASSIGNEE)
Signature

S.C. SUH CFO
Printed Name, Title